Cargando…
Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation
BACKGROUND: Antigen-loaded dendritic cells (DC) are capable of priming naïve T cells and therefore represent an attractive adjuvant for vaccine development in anti-tumor immunotherapy. Numerous protocols have been described to date using different maturation cocktails and time periods for the induct...
Autores principales: | Bürdek, Maja, Spranger, Stefani, Wilde, Susanne, Frankenberger, Bernhard, Schendel, Dolores J, Geiger, Christiane |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955579/ https://www.ncbi.nlm.nih.gov/pubmed/20920165 http://dx.doi.org/10.1186/1479-5876-8-90 |
Ejemplares similares
-
NOD/scid IL-2Rg(null )mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo
por: Spranger, Stefani, et al.
Publicado: (2012) -
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure
por: Wilde, Susanne, et al.
Publicado: (2012) -
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
por: Sailer, Nadja, et al.
Publicado: (2022) -
Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo
por: Wehner, Carina, et al.
Publicado: (2014) -
Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission
por: Beck, Barbara, et al.
Publicado: (2011)